KENALOG

Kenalog Adverse Events Reported to the FDA Over Time

How are Kenalog adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Kenalog, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Kenalog is flagged as the suspect drug causing the adverse event.

Most Common Kenalog Adverse Events Reported to the FDA

What are the most common Kenalog adverse events reported to the FDA?

Injection Site Atrophy	169 (2.71%)
Endophthalmitis	132 (2.11%)
Injection Site Reaction	99 (1.58%)
Drug Ineffective	82 (1.31%)
Visual Acuity Reduced	82 (1.31%)
Headache	73 (1.17%)
Injection Site Pain	65 (1.04%)
Pain	65 (1.04%)
Dizziness	64 (1.02%)
Dyspnoea	62 (.99%)
Injection Site Discolouration	59 (.94%)
	Show More
Vision Blurred	59 (.94%)
Eye Inflammation	58 (.93%)
Muscle Atrophy	56 (.9%)
Nausea	54 (.86%)
Insomnia	48 (.77%)
Intraocular Pressure Increased	46 (.74%)
Swelling Face	45 (.72%)
Pruritus	43 (.69%)
Anaphylactic Reaction	42 (.67%)
Flushing	42 (.67%)
Rash	41 (.66%)
Skin Discolouration	41 (.66%)
Staphylococcal Infection	41 (.66%)
Arthralgia	40 (.64%)
Hypersensitivity	40 (.64%)
Muscle Spasms	40 (.64%)
Retinal Detachment	40 (.64%)
Blindness	38 (.61%)
Weight Increased	38 (.61%)
Pain In Extremity	37 (.59%)
Depression	36 (.58%)
Atrophy	35 (.56%)
Blood Pressure Increased	35 (.56%)
Medication Error	35 (.56%)
Menorrhagia	35 (.56%)
Erythema	34 (.54%)
Asthenia	33 (.53%)
Back Pain	33 (.53%)
Contusion	33 (.53%)
Fatigue	33 (.53%)
Paraesthesia	33 (.53%)
Hypoaesthesia	32 (.51%)
Weight Decreased	32 (.51%)
Alopecia	31 (.5%)
Muscular Weakness	31 (.5%)
Urticaria	31 (.5%)
Anxiety	30 (.48%)
Skin Atrophy	30 (.48%)
Menstruation Irregular	29 (.46%)
Hyperhidrosis	28 (.45%)
Skin Disorder	28 (.45%)
Hypopyon	26 (.42%)
Oedema Peripheral	26 (.42%)
Vomiting	26 (.42%)
Glaucoma	25 (.4%)
Feeling Abnormal	24 (.38%)
Blood Glucose Increased	23 (.37%)
Ocular Hypertension	23 (.37%)
Post Procedural Complication	23 (.37%)
Heart Rate Increased	22 (.35%)
Chest Discomfort	21 (.34%)
Cushingoid	21 (.34%)
Incorrect Route Of Drug Administrat...	21 (.34%)
Injection Site Swelling	21 (.34%)
Palpitations	21 (.34%)
Cataract	20 (.32%)
Drug Administration Error	20 (.32%)
Mood Swings	20 (.32%)
Streptococcal Infection	20 (.32%)
Hypertension	19 (.3%)
Inflammation	19 (.3%)
Retinal Pigment Epithelial Tear	19 (.3%)
Skin Exfoliation	19 (.3%)
Burning Sensation	18 (.29%)
Eye Infection	18 (.29%)
Loss Of Consciousness	18 (.29%)
Malaise	18 (.29%)
Night Sweats	18 (.29%)
Pyrexia	18 (.29%)
Injection Site Inflammation	17 (.27%)
Maculopathy	17 (.27%)
Retinal Haemorrhage	17 (.27%)
Chorioretinal Disorder	16 (.26%)
Lipoatrophy	16 (.26%)
Abdominal Distension	15 (.24%)
Decreased Appetite	15 (.24%)
Dry Skin	15 (.24%)
Injection Site Induration	15 (.24%)
Menstrual Disorder	15 (.24%)
Product Quality Issue	15 (.24%)
Transmission Of An Infectious Agent...	15 (.24%)
Rash Pruritic	14 (.22%)
Skin Hypopigmentation	14 (.22%)
Spinal Cord Infarction	14 (.22%)
Convulsion	13 (.21%)
Diarrhoea	13 (.21%)
Drug Interaction	13 (.21%)
Feeling Hot	13 (.21%)
Hair Growth Abnormal	13 (.21%)
Osteitis	13 (.21%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Kenalog, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Kenalog is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Kenalog

What are the most common Kenalog adverse events reported to the FDA?

Administration Site Reactions	550 (8.8%)
Epidermal And Dermal Conditions	359 (5.75%)
Infections - Pathogen Unspecified	341 (5.46%)
Neurological	270 (4.32%)
Vision	231 (3.7%)
Respiratory	162 (2.59%)
Muscle	148 (2.37%)
Gastrointestinal Signs	146 (2.34%)
Therapeutic And Nontherapeutic Effe...	141 (2.26%)
Medication Errors	140 (2.24%)
Ocular Infections, Irritations And ...	140 (2.24%)
	Show More
Ocular Structural Change, Deposit A...	129 (2.06%)
Skin Appendage Conditions	124 (1.98%)
Musculoskeletal And Connective Tiss...	119 (1.9%)
Bacterial Infectious	111 (1.78%)
Allergic Conditions	106 (1.7%)
Menstrual Cycle And Uterine Bleedin...	98 (1.57%)
Injuries	89 (1.42%)
Headaches	85 (1.36%)
Physical Examination Topics	81 (1.3%)
Cardiac And Vascular Investigations	73 (1.17%)
Joint	73 (1.17%)
Eye	67 (1.07%)
Tissue	62 (.99%)
Anxiety Disorders	61 (.98%)
Vascular	59 (.94%)
Sleep Disorders	57 (.91%)
Retina, Choroid And Vitreous Hemorr...	56 (.9%)
Anterior Eye Structural Change, Dep...	55 (.88%)
Procedural And Device Related Injur...	51 (.82%)
Neurological, Special Senses And Ps...	50 (.8%)
Glaucoma And Ocular Hypertension	48 (.77%)
Adrenal Gland	47 (.75%)
Movement Disorders	47 (.75%)
Cornification And Dystrophic Skin	46 (.74%)
Mood Disorders	45 (.72%)
Angiedema And Urticaria	41 (.66%)
Spinal Cord And Nerve Root	40 (.64%)
Urinary Tract Signs	39 (.62%)
Depressed Mood Disorders	37 (.59%)
Bone Disorders	36 (.58%)
Appetite And General Nutritional	29 (.46%)
Cardiac Arrhythmias	29 (.46%)
Endocrine Investigations	29 (.46%)
Gastrointestinal Motility And Defec...	28 (.45%)
Ocular Neuromuscular	27 (.43%)
Metabolic, Nutritional And Blood Ga...	26 (.42%)
Pigmentation	26 (.42%)
Vulvovaginal Disorders	26 (.42%)
Hematology Investigations	25 (.4%)
Skin And Subcutaneous Tissue	25 (.4%)
Fungal Infectious	24 (.38%)
Skin Vascular Abnormalities	24 (.38%)
Glucose Metabolism Disorders	23 (.37%)
Oral Soft Tissue Conditions	23 (.37%)
Cardiac Disorder Signs	22 (.35%)
Deliria	22 (.35%)
Vascular Hypertensive	22 (.35%)
Viral Infectious	22 (.35%)
Decreased And Nonspecific Blood Pre...	21 (.34%)
Body Temperature Conditions	20 (.32%)
Product Quality Issues	20 (.32%)
Mental Impairment	18 (.29%)
Seizures	18 (.29%)
Bronchial Disorders	17 (.27%)
Upper Respiratory Tract Disorders	17 (.27%)
Hepatobiliary	16 (.26%)
Ancillary Infectious Topics	15 (.24%)
Arteriosclerosis, Stenosis, Vascula...	15 (.24%)
Central Nervous System Vascular	15 (.24%)
Fatal Outcomes	15 (.24%)
Lifestyle Issues	15 (.24%)
Electrolyte And Fluid Balance Condi...	14 (.22%)
Menopause And Related Conditions	14 (.22%)
Microbiology And Serology	13 (.21%)
Salivary Gland Conditions	13 (.21%)
Chemical Injury And Poisoning	12 (.19%)
Dental And Gingival Conditions	12 (.19%)
Gastrointestinal Hemorrhages	12 (.19%)
Inner Ear And Viiith Cranial Nerve	12 (.19%)
Peripheral Neuropathies	12 (.19%)
Embolism And Thrombosis	11 (.18%)
Therapeutic Procedures And Supporti...	11 (.18%)
Tongue Conditions	11 (.18%)
Water, Electrolyte And Mineral	11 (.18%)
Disturbances In Thinking	10 (.16%)
Reproductive Tract	10 (.16%)
Musculoskeletal And Connective Tiss...	9 (.14%)
Ocular Hemorrhages And Vascular	9 (.14%)
Vascular Hemorrhagic	9 (.14%)
Gastrointestinal Conditions	8 (.13%)
Neuromuscular	8 (.13%)
Suicidal And Self-injurious Behavio...	8 (.13%)
Vascular Inflammations	8 (.13%)
Breast	7 (.11%)
Exocrine Pancreas Conditions	7 (.11%)
Gastrointestinal Ulceration And Per...	7 (.11%)
Lower Respiratory Tract Disorders	7 (.11%)
Psychiatric	7 (.11%)
Renal Disorders	7 (.11%)
Synovial And Bursal	7 (.11%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Kenalog, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Kenalog is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.